Representation of NMDP/Be The Match donor collection network

Managing donor collections during the COVID-19 pandemic

Even before COVID-19 reached pandemic levels, teams at the National Marrow Donor Program® (NMDP)/Be The Match® had their eye on an important part of the cell therapy supply chain—donor collections. Collections from allogeneic donors are critical to getting time-sensitive life-saving cell therapies to patients around the world. But donors often must fly to the apheresis…

COVID-19

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Updated March 27, 2020 (original story follows) Editor’s note: It’s been just over one month since we first shared how established relationships have helped our organization navigate the impacts of the coronavirus on the cell therapy supply chain. Since then, much has changed. Just a few days after we posted the story, reports from Italy…

HLA matching could bring more allogeneic cell therapies to market, faster

The emergence of novel cell therapy technologies has led to questions about the necessity of human leukocyte antigen matching (HLA matching) in the development of potential “universal” allogeneic cell therapies. After all, if you can eliminate alloreactive responses, what role would HLA matching play? Martin Maiers, MS, is the Vice President of Biomedical Informatics for…

How to overcome 3 common cell therapy supply chain disruptions

One patient, one product. The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, an advanced approach is needed to overcome supply chain disruptions that create barriers to successful on-time delivery. Severe weather, customs complexities and flight delays are three…